ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
Launched by ACADIA PHARMACEUTICALS INC. · Dec 22, 2023
Trial Information
Current as of June 28, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Subject has successfully completed ACP-204-006 study
- • Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential
- • Subject has a designated study partner/caregiver
- • Subjects are able to complete all study visits with a study partner/caregiver
- • Signed inform consent form with a caregiver or legal representative
- Exclusion Criteria:
- • Requires treatment with a medication prohibited by the protocol
- • Is in hospice and receiving end-of-life palliative care, or has become bedridden
- • Female who is pregnant or breastfeeding
- • Unstable clinically significant medical condition other than AD
- • Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study
- • Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.
About Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for central nervous system (CNS) disorders. With a strong focus on advancing treatments for conditions such as Parkinson's disease psychosis, schizophrenia, and other neurodegenerative diseases, Acadia leverages cutting-edge science and clinical expertise to address unmet medical needs. The company's commitment to rigorous research and patient-centric approaches aims to improve the quality of life for individuals affected by complex neurological conditions, positioning Acadia as a leader in the CNS therapeutic area.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Paris, , France
Kaohsiung, , Taiwan
Abington, Pennsylvania, United States
Miami, Florida, United States
Seoul, , Korea, Republic Of
Costa Mesa, California, United States
Seoul, , Korea, Republic Of
Incheon, , Korea, Republic Of
Santiago, , Chile
Porto Alegre, Rs, Brazil
Toulouse, , France
Seoul, , Korea, Republic Of
Pleven, , Bulgaria
Kaohsiung City, , Taiwan
Brescia, , Italy
Hialeah, Florida, United States
Kladno, , Czechia
Sofia, , Bulgaria
Santiago, , Chile
Antofagasta, , Chile
Miami, Florida, United States
Garden Grove, California, United States
Miami, Florida, United States
Rio De Janeiro, , Brazil
Sofia, , Bulgaria
Hialeah, Florida, United States
Miami, Florida, United States
Belgrade, , Serbia
Kaohsiung City, , Taiwan
San Luis Potosí, , Mexico
Curitiba, , Brazil
Pazardzhik, , Bulgaria
Brasília, , Brazil
Monterrey, Nuevo Leon, Mexico
Miami, Florida, United States
Praha 10, , Czechia
Houston, Texas, United States
Sofia, , Bulgaria
Praha, , Czechia
Curitiba, , Brazil
Miami, Florida, United States
Cherven Bryag, , Bulgaria
Salerno, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported